Abyrx, the biosurgical products company focused on delivering safe and effective surgical solutions, has closed a Series b funding round, raising $10.0M. The fresh capital is earmarked to accelerate its mission of providing tools that not only benefit patients but also offer surgeons superior alternatives to existing products and prove cost-effective for administrators.
The company, guided by a seasoned management team of physicians, Ph.D.'s, and business leaders, is now better positioned to advance its product development and market entry in the competitive biosurgical space.
